It’s not day-after-day in pharma {that a} new class of medication enters the pantheon of the best-selling drugs of all time. However the emergence of Eli Lilly’s Zepbound and Mounjaro and Novo Nordisk’s Ozempic and Wegovy took the pharma world by storm. The diabetes and weight problems drugs have helped hundreds of thousands of sufferers handle unmet wants and created wild market demand.
In line with the instances, the PharmaVoice 100 launched a brand new class this yr to acknowledge the numerous impression of this market. Meet the Cardiometabolic All-Stars, representing the standouts within the sector making large waves.
Some are advancing new therapies to work alongside diabetes and weight reduction leaders, whereas others are forging new remedy paths to enhance upon what’s already on the market. These leaders embrace Massive Pharma gamers making an impression by turning GLP-1s into family names, and people pushing the boundaries with novel approvals.
Listed below are this yr’s Cardiometabolic All-Stars.
Robert Blum
“Biopharma has a approach of humbling even the very best and brightest chief amongst us.” Learn extra ➔
Kristen Fortney
“Ageing biology will yield a wealth of novel targets that may enhance well being span on a broad scale.” Learn extra ➔
Vipin Garg
“It’s thrilling to see extra emphasis being positioned on [R&D] … to enhance the standard and longevity of life.” Learn extra ➔
Negelle Morris
“Nice leaders acknowledge the importance of fostering real connections inside organizations.” Learn extra ➔
Rohan Palekar
“We’re in an period of exceptional medical innovation, with discovery of latest therapies and functions of latest modalities to increase lives.” Learn extra ➔
Dr. Rebecca Taub
“The power to endure and adapt whereas sustaining a transparent [scientific] imaginative and prescient is what brings progressive therapies to sufferers.” Learn extra ➔